[The antimutagenic activity of afobazol studied in vivo].
The chromosome aberration assay in the bone marrow cells of C57B1/6 mice showed that the new 2-mercaptobenzimidazole derivative afobazole(1-100 mg/kg) prevented manifestations of the clastogenic effects of dioxidine (100 mg/kg, i.p.) over a period of 24 h and reduced by 44-75% the cytogenetic effect of dioxidine (300 mg/kg, i.p.). The same doses of afobazole produced a statistically significant decrease in the cyclophosphamide (20 mg/kg, i.p.) damage over a period of 24 h. Afobazole showed no inherent mutagen activity and did not potentiate the effects of mutagens studied.
Zhanataev
A K
AK
Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
Durnev
A D
AD
Seredenin
S B
SB
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D016587:Antimutagenic Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000187:drug effects; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009025:Morpholines / Q000494:pharmacology*; D009153:Mutagens / Q000633:toxicity; D011810:Quinoxalines / Q000633:toxicity
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D016587:Antimutagenic Agents; D001562:Benzimidazoles; D009025:Morpholines; D009153:Mutagens; D011810:Quinoxalines; C001077:dioxidine; D003520:Cyclophosphamide